Company intelligence / Profile preview

Rapidx Bio

Cambridge, England, United Kingdomrapidx.io ↗

Ownership: Private
Development stage: Other

Overview

Rapidx Bio is developing a plasmonic PCR-based diagnostic device that enables symptom-to-treatment cycles for infectious diseases to be reduced from 8–16 days to under 30 minutes. The technology leverages lasers and nanotechnology for rapid disease detection at the point of care. No published clinical results yet; company is in development and early deployment phase.

Therapeutic areas: Infectious Diseases
Modalities: DeviceNanotechnology-based diagnostics (Plasmonic PCR)
Industry: Molecular Diagnostics

Partnerships

University of CambridgeImperial College London IncubatorEntrepreneur First accelerator program

Beyond the preview

Go deeper on Rapidx Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rapidx Bio.

Explore the full profile